Comment
doi: 10.1001/jama.2017.18312.
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer
Affiliations
- PMID: 29340668
- DOI: 10.1001/jama.2017.18312
Item in Clipboard
Comment
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer
JAMA.
.
No abstract available
Comment in
-
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.JAMA. 2018 Jan 16;319(3):306-307. doi: 10.1001/jama.2017.18318. JAMA. 2018. PMID: 29340672 No abstract available.
Comment on
-
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. JAMA. 2017. PMID: 28898379 Free PMC article. Clinical Trial.
Similar articles
-
[Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].Orv Hetil. 2013 Dec 8;154(49):1934-42. doi: 10.1556/OH.2013.29765. Orv Hetil. 2013. PMID: 24292111 Clinical Trial. Hungarian.
-
Pilot study comparing the accuracy of lymphoscintigraphy sentinel lymph node localisation with axillary node dissection in women with operable breast cancer.N Z Med J. 2001 May 25;114(1132):233-6. N Z Med J. 2001. PMID: 11453361
-
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.JAMA. 2018 Jan 16;319(3):306-307. doi: 10.1001/jama.2017.18318. JAMA. 2018. PMID: 29340672 No abstract available.
-
[Sentinel lymph node status and axillary lymph node dissection in the surgical treatment of breast cancer].Orv Hetil. 2014 Feb 9;155(6):203-15. doi: 10.1556/OH.2014.29816. Orv Hetil. 2014. PMID: 24486844 Review. Hungarian.
-
The need for lymph node dissection in nonmetastatic breast cancer.Annu Rev Med. 2013;64:119-29. doi: 10.1146/annurev-med-052511-135500. Epub 2012 Sep 27. Annu Rev Med. 2013. PMID: 23020881 Review.
Cited by
-
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes.JNCI Cancer Spectr. 2019 Aug 1;3(4):pkz058. doi: 10.1093/jncics/pkz058. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337484 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
